相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Monica R. Gadelha et al.
ENDOCRINE REVIEWS (2019)
Glycemic Targets: Standards of Medical Care in Diabetes-2019
William T. Cefalu et al.
DIABETES CARE (2019)
How to Position Pasireotide LAR Treatment in Acromegaly
Eva C. Coopmans et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial
Andre Lacroix et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Carla Scaroni et al.
ENDOCRINE REVIEWS (2017)
Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly
Julie M. Silverstein
PITUITARY (2016)
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
Michael Sheppard et al.
PITUITARY (2015)
Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study
Astrid Breitschaft et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients
Orsalia Alexopoulou et al.
PITUITARY (2014)
Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations
Annamaria Colao et al.
PITUITARY (2014)
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Monica R. Gadelha et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers
Robert R. Henry et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
Annamaria Colao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Mortality and Morbidity in Cushing's Disease over 50 Years in Stoke-on-Trent, UK: Audit and Meta-Analysis of Literature
R. N. Clayton et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Incretin-Based Therapies Viewpoints on the way to consensus
Michael A. Nauck et al.
DIABETES CARE (2009)
The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas
Dalia L. Batista et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5
LJ Hofland et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro
LJ Hofland et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Pathology of pituitary tumors
N Sanno et al.
NEUROSURGERY CLINICS OF NORTH AMERICA (2003)
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
C Bruns et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
分享论文
